Huntington Ingalls Industries' AMSEC Subsidiary Wins Navy

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Huntington Ingalls Industries' AMSEC Subsidiary Wins Navy CEMAT and SEMAT Contract

VIRGINIA BEACH, Va., April 7, 2014 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE: HII ) announced today that its AMSEC subsidiary has been awarded a contract to provide engineering, technical, repair and logistics support to the U.S. Navy's Carrier Engineering Maintenance Assist Team (CEMAT) and Surface Ship Engineering Maintenance Assist Team (SEMAT) programs. The indefinite-delivery/indefinite-quantity, cost-plus-fixed-fee contract contains a one-year base period with four one-year option periods, which, if exercised, would bring the cumulative value of the contract to more than $187 million.

"AMSEC has brought continuity and innovation to the CEMAT and SEMAT programs, and we are delighted to have won this contract," said Harris Leonard, vice president of HII's Newport News Shipbuilding division and president of AMSEC operations. "Being selected by the Navy to continue this support makes us very proud of our past performance and has us looking forward to providing continued support to the fleet."

AMSEC will furnish engineering and technical services in support of maintenance and planning for the overhaul and repair of equipment and systems associated with the Navy's aircraft carriers and West Coast surface ships.

"We are very pleased to continue our CEMAT support to the Navy's aircraft carriers and SEMAT support to its west coast surface ships," said Brad Mason, director of AMSEC's maintenance, modernization and technical services operation. "Our technicians are part of the valuable 'find-fix-and-train' philosophy the program has provided for almost 30 years. As the Navy faces both budget and size restrictions, AMSEC is proud to be part of this maintenance philosophy while providing valuable training to the sailors who operate the critical systems covered by this contract."

Work will be performed in various ship homeports throughout the world. If all options are awarded, the work is expected to be completed by April 2019. The Norfolk Ship Support Activity in Virginia is the contracting activity.

AMSEC LLC is a subsidiary of Huntington Ingalls Industries. With over 2,000 employees in 33 locations nationwide and overseas, AMSEC is a full-service supplier to the Navy and commercial maritime industry, providing naval architecture and marine engineering, naval ship systems assessments, maintenance engineering, waterfront maintenance support, acquisition program support, shipyard industrial engineering, and C4I installation and support services. AMSEC also provides life-cycle integrated logistics services, including technical manual development, provisioning documentation, spare parts management, training development and delivery, and software development.

Huntington Ingalls Industries designs, builds and maintains nuclear and non-nuclear ships for the U.S. Navy and Coast Guard and provides after-market services for military ships around the globe. For more than a century, HII has built more ships in more ship classes than any other U.S. naval shipbuilder at its Newport News Shipbuilding and Ingalls Shipbuilding divisions. Employing more than 38,000 in Virginia, Mississippi, Louisiana and California, HII also provides a wide variety of products and services to the commercial energy industry and other government customers, including the Department of Energy. For more information about HII, visit:

Statements in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those expressed in these statements. Factors that may cause such differences include: changes in government and customer priorities and requirements (including government budgetary constraints, shifts in defense spending, and changes in customer short-range and long-range plans); our ability to obtain new contracts, estimate our costs and perform effectively; risks related to our spin-off from Northrop Grumman (including our increased costs and leverage); our ability to realize the expected benefits from consolidation of our Gulf Coast facilities; natural disasters; adverse economic conditions in the United States and globally; and other risk factors discussed in our filings with the U.S. Securities and Exchange Commission. There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business, and we undertake no obligations to update any forward-looking statements.

CONTACT: Christie Miller Christine.Miller@HII-co.com (757) 380-3581

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 421

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 34

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 536

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 462

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 547

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 308

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 243

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Silexion Therapeutics to Showcase Innovations at Upcoming Conference

Updated Category News Views 127

Silexion Therapeutics and Its Future in Oncology Silexion Therapeutics Corp. is at the forefront of the biotechnology sector, focusing its efforts on innovative treatments specifically designed for oncology. This clinical-stage company is dedicated to transforming the landscape for patients with hard-to-treat cancers, primarily those with the mutated KRAS oncogene, known...

Continue Reading
UBS Predicts Slowdown in Nvidia-Led Tech Rally - Key Insights

Updated Category News Views 172

UBS Foresees Changes in Tech Rally Dynamics Analysts at UBS suggest that the excitement surrounding the recent tech rally, driven by Nvidia, is beginning to wane. They predict a shift towards a more volatile market environment, influenced by ongoing economic challenges and increasing regulatory scrutiny in the semiconductor sector. Analysts' Perspectives on Future Stock...

Continue Reading
OS Therapies (OSTX) Unveils Encouraging Survivorship Data

Updated Category News Views 222

OS Therapies Inc. Reports Promising Results in Bone Cancer Therapy OS Therapies Inc. (NYSE: OSTX), a company focused on developing innovative cancer treatments, recently reported compelling findings from its Phase 2b clinical trial on OST-HER2, an off-the-shelf immunotherapy designed for addressing osteosarcoma, a challenging form of bone cancer. Significant Survival Data...

Continue Reading
Jeito Capital Boosts Aviceda Therapeutics with $207.5M Funding

Updated Category News Views 239

Jeito Capital's Strategic Investment in Aviceda Therapeutics Jeito Capital has recently announced a significant investment in Aviceda Therapeutics, securing a substantial participation in an upsized $207.5 million Series C financing round aimed at advancing the company's lead program, AVD-104. This funding is specifically intended to support pivotal trials for AVD-104,...

Continue Reading
Apple's Innovative M4 Mac Mini Sets New Standards in Tech

Updated Category News Views 293

Apple Launches the Game-Changing Mac Mini Apple Inc (NASDAQ: AAPL) has once again captivated technology enthusiasts and consumers alike with its latest innovation — the redesigned Mac mini equipped with groundbreaking M4 and M4 Pro chips. This launch not only showcases Apple's commitment to performance but also its pioneering approach to sustainability, marking the Mac...

Continue Reading